<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04695795</url>
  </required_header>
  <id_info>
    <org_study_id>1236</org_study_id>
    <nct_id>NCT04695795</nct_id>
  </id_info>
  <brief_title>Sea Water in Allergic Conjunctivitis</brief_title>
  <official_title>Efficacy and Safety of Seawater in Allergic Conjunctivitis. IgE and MMP-9 Tear Levels. Antihistaminic Eyedrops Comparative Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Valencia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Valencia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background and purpose: Allergic conjunctivitis has increased alarmingly in recent years. The&#xD;
      objectives of the study are: 1) To establish the safety and efficacy of applying eyewashes in&#xD;
      spray form as monotherapy on the symptoms and signs of allergic conjunctivitis; 2) To&#xD;
      establish the comparative efficacy with other eye drops as antihistamines; 3) To measure the&#xD;
      modification of immunoglobulin E (IgE) and matrix metalloproteinase 9 (MMP9) levels in the&#xD;
      tears.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Material and methods: Prospective study. A total of 50 patients will be included. A scale&#xD;
      from 0 to +3 will be established to quantify the intensity of the different parameters&#xD;
      measured. A total of 8 symptoms will be studied - itching, tearing, mucous secretions,&#xD;
      photophobia, foreign body sensation, redness, rubbing, palpebral swelling, and 3 signs -&#xD;
      palpebral papillae, conjunctival hyperemia, and corneal involvement (dotted keratitis).&#xD;
      Control at 30 minutes, 1 day, and 1 month after the application of the treatment. At the end&#xD;
      of the treatment period, the degree of satisfaction with the treatment, the desire to&#xD;
      continue or abandon it, and the need to associate other complementary treatments due to lack&#xD;
      of control will also be evaluated. All patients will be treated exclusively with seawater&#xD;
      isotonic solution in the form of a spray 5 times a day for 1 month. A second similar group of&#xD;
      patients will be treated with antihistamine eye drops and a third group of patients with both&#xD;
      antihistamine eye drops and seawater. Tears measurement of immunoglobulin E and matrix&#xD;
      metalloproteinase 9 levels will be measured before and after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Measure the symptoms, and corneal and conjunctival signs before and after treatment, Bonini scale</measure>
    <time_frame>1 month</time_frame>
    <description>A scale from 0 to +3 will be established to quantify the intensity of the different parameters measured. A total of 8 symptoms will be studied - itching, tearing, mucous secretions, photophobia, foreign body sensation, redness, rubbing, palpebral swelling, and 3 signs - palpebral papillae, conjunctival hyperemia, and corneal involvement (dotted keratitis).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure metalloproteinase 9 in tears before and after treatment</measure>
    <time_frame>1 month</time_frame>
    <description>To administer the test, physician collects a tear sample, then activates it with a buffer solution. In 10 minutes, the test will be ready, and will either show a solitary blue line, indicating a negative result, or a blue line accompanied by a red line, which is positive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure immunoglobulin E in tears before and after treatment</measure>
    <time_frame>1 month</time_frame>
    <description>A strip is placed in the lower conjunctival fornix and, when wet with tears, is removed. Signal intensity is dependent on the total Immunoglobulin E level.</description>
  </primary_outcome>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Allergic Conjunctivitis</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      IgE and MMP9&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Allergic conjunctivitis patientes from 10 yeras old and older&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        The inclusion criteria were patients with mild or moderate allergic conjunctivitis as&#xD;
        detailed in Table I. The minimum to be included in the study was the presence in both eyes&#xD;
        of three symptoms and one sign (Table II). Among the symptoms, the presence of itching and&#xD;
        two more of the following were essential: redness, tearing, foreign body sensation,&#xD;
        rubbing, mucous secretion, and/or palpebral swelling sensation. Among the signs,&#xD;
        conjunctival hyperemia, papillae in the palpebral conjunctiva, and/or corneal affectation&#xD;
        in the form of dotted keratitis were evaluated.&#xD;
&#xD;
        Table 1 Degree of conjunctivitis I Mild II Moderate III Severe IV Blinding&#xD;
&#xD;
        Conjunctiva bulbar: congestion granuloma Conjunctiva tarsal: micropapillae 1mm giant &gt;1 mm&#xD;
        cobblestone Corneal staining : micro macro shield ulcer Limbal affectation: &lt; 180 degrees&#xD;
        &gt;180 degrees insufficiency limbo/pannus/ vascularization corneal&#xD;
&#xD;
        Table 2 Signs and symptoms evaluated initially and at each visit&#xD;
&#xD;
        Symptoms Signs:&#xD;
&#xD;
          -  Itching - Conjunctival Hyperemia&#xD;
&#xD;
          -  Redness - Pads&#xD;
&#xD;
          -  Foreign body sensation - palpebral swelling&#xD;
&#xD;
          -  Photophobia&#xD;
&#xD;
          -  Eyelid swollen sensation&#xD;
&#xD;
          -  Mucous secretions&#xD;
&#xD;
          -  Rubbing&#xD;
&#xD;
          -  Tears&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  blepharitis&#xD;
&#xD;
          -  meibomian gland dysfunction syndrome (MGS)&#xD;
&#xD;
          -  dry eye disease&#xD;
&#xD;
          -  topical eye drug such as cyclosporine, tacrolimus, interferon-alpha, mitomycin&#xD;
&#xD;
          -  previous eye surgery&#xD;
&#xD;
          -  corneal refractive surgery.&#xD;
&#xD;
          -  use of contact lenses&#xD;
&#xD;
          -  glaucoma&#xD;
&#xD;
          -  pterygium&#xD;
&#xD;
          -  ocular pemphigoid&#xD;
&#xD;
          -  anti-allergic vaccines&#xD;
&#xD;
          -  oral or subcutaneous drugs such as antihistamines, anti-leukotrienes (montelukast),&#xD;
             corticoids, immunosuppressants or biological drugs.&#xD;
&#xD;
          -  rhinitis and dermatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>10 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>mariadolores pinazoduran, MD,Prof</last_name>
    <role>Study Chair</role>
    <affiliation>University of Valencia, Spain</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Manuel J Diaz-Llopis, MD,Prof</last_name>
    <phone>+34666530085</phone>
    <email>manuel.diaz@uv.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariamparo D Guiñoncampos, MD,Prof</last_name>
    <phone>+34687962998</phone>
    <email>amparo.gc@hotmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Bonini S, Sacchetti M, Mantelli F, Lambiase A. Clinical grading of vernal keratoconjunctivitis. Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):436-41. Review.</citation>
    <PMID>17873585</PMID>
  </reference>
  <reference>
    <citation>Yazu H, Kozuki N, Dogru M, Shibasaki A, Fujishima H. The Effect of Long-Term Use of an Eyewash Solution on the Ocular Surface Mucin Layer. Int J Mol Sci. 2019 Oct 13;20(20). pii: E5078. doi: 10.3390/ijms20205078.</citation>
    <PMID>31614909</PMID>
  </reference>
  <reference>
    <citation>Yazu H, Dogru M, Matsumoto Y, Fujishima H. Efficacy and safety of an eye wash solution in allergic conjunctivitis after conjunctival allergen challenge. Ann Allergy Asthma Immunol. 2016 Nov;117(5):565-566. doi: 10.1016/j.anai.2016.08.030. Epub 2016 Oct 24.</citation>
    <PMID>27788889</PMID>
  </reference>
  <reference>
    <citation>Gokhale NS. Systematic approach to managing vernal keratoconjunctivitis in clinical practice: Severity grading system and a treatment algorithm. Indian J Ophthalmol. 2016 Feb;64(2):145-8. doi: 10.4103/0301-4738.179727.</citation>
    <PMID>27050351</PMID>
  </reference>
  <reference>
    <citation>Yaşar M, Uysal IÖ, Altuntaş EE, Cevit Ö, Müderris S. Effects of topical sprays on allergy-induced nasal obstruction in children. Kulak Burun Bogaz Ihtis Derg. 2013 Jul-Aug;23(4):217-24. doi: 10.5606/kbbihtisas.2013.27132.</citation>
    <PMID>23834132</PMID>
  </reference>
  <reference>
    <citation>Dermer H, Theotoka D, Lee CJ, Chhadva P, Hackam AS, Galor A, Kumar N. Total Tear IgE Levels Correlate with Allergenic and Irritating Environmental Exposures in Individuals with Dry Eye. J Clin Med. 2019 Oct 4;8(10). pii: E1627. doi: 10.3390/jcm8101627.</citation>
    <PMID>31590324</PMID>
  </reference>
  <reference>
    <citation>Kumagai N, Yamamoto K, Fukuda K, Nakamura Y, Fujitsu Y, Nuno Y, Nishida T. Active matrix metalloproteinases in the tear fluid of individuals with vernal keratoconjunctivitis. J Allergy Clin Immunol. 2002 Sep;110(3):489-91.</citation>
    <PMID>12209100</PMID>
  </reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>January 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>January 4, 2021</last_update_submitted>
  <last_update_submitted_qc>January 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seawater</keyword>
  <keyword>allergic conjunctivitis</keyword>
  <keyword>IgE tear level</keyword>
  <keyword>MMP9 tear level</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

